EBNA-1 anticorps (AA 551-641)

N° du produit ABIN1385109

Cet anticorps anti-EBNA-1 Polyclonal Lapin (ABIN1385109) détecte spécifiquement EBNA-1 dans WB, IF (cc), IF (p), IHC (p) et IHC (fro). L’anticorps est réactif avec des échantillons de Epstein-Barr Virus (EBV).

Aperçu rapide pour EBNA-1 anticorps (AA 551-641) (ABIN1385109)

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Reactivité: Epstein-Barr Virus (EBV)

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EBNA-1 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-EBNA-1 anticorps

Épitope: AA 551-641

Fonction: EBV Nuclear Antigen Polyclonal Antibody

Réactivité croisée: Virus

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Isotype: IgG

Information d'application

Indications d'application: WB(1:500-1000),

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Détails sur EBNA-1

Antigène: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Autre désignation: EBV Nuclear Antigen

Classe de substances: Viral Protein

Sujet:

Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,

Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.